Is the second bite of the apple real?

What is the second bite, and why is it the whole pitch?

When you sell to a private equity backed platform, you receive most of your price in cash and the rest as rollover equity, usually 20 to 40 percent, in the buyer's holding company. The rollover equity page explains what those units are. The second bite of the apple is what happens to them when the fund sells the platform: your units are bought out too, and you receive a second payment, hopefully at a higher value than the one you rolled in at.

The second bite is how buyers justify a price that, in cash terms, is a multiple of the income you are giving up. The argument is that the platform will grow, the multiple will hold or rise, and your 30 percent will be worth more than the 30 percent you gave up. In the best years of this market, that was often true. The question for anyone selling in 2026 is whether the conditions that made it true still hold.

What does the data say about resales?

The best published study is by Singh, Zhu, and colleagues in Health Affairs Scholar (April 2024). It tracked 807 private equity acquisitions of dermatology, ophthalmology, and gastroenterology practices from 2016 through 2020. Of those practices, 51.6 percent changed hands again within three years of the first sale. The median hold was 2.9 years. Of the resales, 97.8 percent were to another private equity firm rather than to a hospital, a strategic company, or the physicians themselves.

Two things stand out. First, resales were fast and common in that period, which is why the second bite became a standard part of every sales pitch. Second, the buyer at the second sale was almost always another fund, which means the physician's units were often rolled into the new owner's structure rather than fully cashed out. The study measures ownership changes, not physician payouts. No dataset we have found shows how often physician rollover actually turned into cash.

Why did recaps collapse after 2022?

Platform recapitalizations, the PE-to-PE sales that produce a second bite, ran at roughly 100 a year in 2021 and 2022. In 2024 there were 13. Interest rates rose, which made the debt that funds use to buy platforms more expensive and made buyers less willing to pay the multiples of 2021. Public healthcare services companies traded at a median of about 11.5 times EBITDA in 2025, down from 14.5 times in 2024. A fund that bought a dermatology platform at 14 times in 2021 does not want to sell at 11 times in 2025, so it waits.

The result is the honest statement that should be on every term sheet. The 2016 to 2020 cohort largely got a second bite. The 2021 and 2022 cohort largely has not yet. Historical hold periods of 5 to 7 years have stretched to 8 to 10. Foley reported in July 2026 that 26.9 percent of US private equity portfolio companies were seven or more years old at the start of 2026. If you rolled in 2021, your fund is now in year five with no obvious buyer at the price it needs.

Deal flow into new platforms has slowed too. PitchBook counted 851 physician practice management deals in 2021 and roughly 390 in 2025, and projects a further drop of roughly 46 percent in 2026. Fewer new deals means fewer funds building platforms that need to buy add-ons, which is another reason exits are slower.

Who is still exiting, and at what price?

The market has split in two. Ordinary PE-to-PE recaps are scarce. Large exits to strategic buyers are happening, at high multiples, in a few specialties. Cardinal Health bought 73 percent of GI Alliance for $2.8 billion in January 2025 and 75 percent of Solaris Health (urology) for $1.9 billion in late 2025. Cencora bought Retina Consultants of America for $4.6 billion plus $500 million contingent in January 2025 and OneOncology for $4.6 billion in February 2026. McKesson bought about 80 percent of PRISM Vision for roughly $850 million in April 2025. Optum's SCA Health bought US Digestive Health and OrthoAlliance. These exits priced at roughly 12 to 18 times EBITDA.

If your platform is a national leader in gastroenterology, urology, retina, or oncology, the second bite has been real and rich. If your platform is a mid-sized dermatology or dental group, the buyers who paid those prices have not shown up. Whether a strategic buyer exists for your specialty is a question to ask before you roll, not after.

What is a continuation fund, and does it count as a second bite?

A continuation fund is a new fund raised by the same private equity firm to buy a company from one of its older funds. The old fund's investors get cash and the firm keeps managing the same company under a new fund with a new clock. From the firm's point of view, it is an exit. From yours, it is often a re-roll: your units convert into units of the new holding company, and you receive little or no cash.

Whether you can elect cash instead depends on your operating agreement. Most agreements include a drag-along right that requires you to sell on the same terms as the sponsor. If the sponsor is taking equity in the new vehicle, you may be required to take equity too. Some agreements let physicians elect cash for a stated portion of their units at any exit. That right has to be negotiated at the first deal. It is nearly impossible to add later.

Does a dividend recap put money in my pocket?

A dividend recapitalization is when the platform borrows money and pays the proceeds out to its owners. It lets the fund return cash to its investors without selling the company. If your units are the same class as the sponsor's, you share in the payout by percentage. If your units are common and sit behind a preferred class, the payout may go to the preferred first and reach you in part or not at all. In either case, the new debt sits ahead of every equity holder when the company is finally sold, so a recap that pays you a little today reduces what your units may be worth later. The Commonwealth Fund's April 2026 study found opaque accounting among the top physician complaints after a sale; a recap you learn about after the fact is a common example.

How is the second bite taxed?

Your basis in the rollover units carried over from your basis in the practice, which for most physicians was close to zero. Nearly the entire second payment is therefore gain. If you have held the units more than a year, the gain is long-term capital gain at 20 percent federal. The 3.8 percent net investment income tax will very likely apply as well. On the first sale, many physicians are exempt from that tax because they materially participate in the business being sold. On the second sale, you are usually a W-2 employee of the MSO, not an active owner of the entity being sold, and if the holdco is a corporation the gain on its stock is investment income by definition. Plan for 23.8 percent federal.

If the holdco is a partnership, Section 751 treats your share of unrealized receivables and depreciation recapture as ordinary income at up to 37 percent, and your annual K-1s may have already included phantom income along the way. State tax applies on top, at your state of residence when the sale occurs, with the important exception that installment payments can trail back to the state where you lived when you sold. The tax pillar page covers the mechanics.

What planning has to happen before the second bite?

Because the second sale is often years away and the units are worth less on paper today than they may be worth later, the years between the first and second bite are the best planning window many physicians will ever have. Three tools depend on acting before a sale is likely.

Gifting units

Units transferred to an irrevocable trust for your children while their value is low, and while minority and marketability discounts apply, move the future appreciation out of your taxable estate. The 2026 federal exemption is $15 million per person; New York's state exemption is $7.35 million with a cliff. The estate planning page works through this, including the transfer restrictions in most operating agreements that require sponsor consent.

Charitable transfers

Units given to a donor-advised fund or a charitable remainder trust before a sale is practically certain can avoid the gain entirely on the gifted portion. The Tax Court's 2023 decision in Estate of Hoensheid denied both the gain avoidance and the deduction where the gift came two days before closing and lacked a qualified appraisal. The window is before the letter of intent for the second sale, not after. See charitable strategies.

Residency

If you plan to retire to a no-tax state, a move completed well before the second sale, with the paper trail to prove it, can remove state tax on the gain. Moving in the year of the sale is the highest audit risk pattern in both California and New York. The California and New York pages explain the residency tests.

How do I budget without the second bite?

Treat the rollover as an option that may pay, not as an asset you can spend. In practice, that means four things.

• Set your retirement date and annual spending using only the after-tax cash from the first sale, your post-sale salary, and your existing savings. Run the calculator with the rollover excluded.
• Expect your salary to fall. Buyers typically take 20 to 30 percent of practice profit as the scrape, and post-sale base pay often runs 40 to 50 percent of total compensation versus 60 to 80 percent before the deal. Income repair is a promise, not a guarantee. The scrape page explains how to plan cash flow through it.
• Keep the rest of your portfolio uncorrelated with the rollover. You already hold a large private position in one healthcare services company. Your other investments should not add to it.
• Reserve for phantom income if the holdco is a partnership. A K-1 with income and no matching cash distribution is a tax bill you must pay from other money.

If the second bite arrives, it can fund an earlier retirement, a larger gift, or a second home. If it does not, nothing in your plan breaks. That asymmetry is the point.

When the second bite question does not apply to you

Not every seller needs to think hard about this.

• If you took no rollover, or the buyer was a hospital or a strategic that paid all cash, there is no second bite to plan around.
• If you are retiring at closing and the good leaver terms give you a repurchase at fair market value on a set date, your exit is contractual rather than dependent on a platform sale, and the analysis is a credit question about the MSO.
• If your rollover is small relative to your net worth, its arrival or absence will not change your plan, and the right amount of attention is very little.

What to do next

1. Find out what cohort you are in

   Ask when the fund that owns your platform was raised and when it bought its first practice. A fund in year six or seven is under pressure to exit; a fund in year two is not.

2. Read your drag-along and re-roll terms

   Find out whether you can elect cash at an exit and for how much of your position. If you have not signed yet, negotiate that right now.

3. Ask about strategic interest in your specialty

   The second bite has been real in GI, urology, retina, and oncology because strategic buyers showed up. Ask your banker or counsel whether any exist for your specialty at your platform's size.

4. Rebuild the plan at zero

   Model your household with the rollover excluded, then start the estate and charitable planning that must be done years before an exit.